俄罗斯疫苗怎么样

俄罗斯疫苗怎么样配图，仅供参考

Russian vaccine
The Sputnik V is a heterologous two-dose virus-vector vaccine developed by the Gamaleya Research Institute. During early development,it attracted criticism from the scientific community because Russia granted it state registration before the phase 3 efficacy trial had even begun. Nonetheless,the vaccine has been shown to be 91.6% effective and is now approved in at least 26 countries. The Russian Direct Investment Fund has sold over 327 million doses of Sputnik V to 22 countries,mostly LMICs,including India,Vietnam,Uzbekistan,Mexico,Nepal,Egypt,Argentina,Venezuela and Brazil. When Argentinas contract negotiation with Pfizer collapsed in 2020,Russia stepped in. On Christmas Day,the first batch of 300 000 doses of Sputnik V was delivered to Buenos Aires on the ‘Flight of Hope’,winning hearts and minds as well as arms. In Hungary,regulators circumvented EU procedures to approve Sputnik V for emergency use and the country became the first EU member to administer the Russian vaccine.","department":"